Value of circulating tumor DNA for the diagnosis of melanoma：a Meta-analysis

doi:10.3969/j.issn.1673-8640.2020.08.010

Abstract

Abstract:

Objective To evaluate the diagnostic value of circulating tumor DNA（ctDNA） for melanoma by a Meta-analysis. Methods Medline,Excerpta Medica Database（Embase）,Cochrane Library database,CNKI database and VIP database were searched systematically to identify studies reporting the diagnostic value of ctDNA for melanoma,until January 2019. The heterogeneity was analyzed by I² and Q tests. The pooled sensitivity,specificity,positive likelihood ratio（PLR）,negative likelihood ratio（NLR）,diagnostic odds ratio（DOR） and the area under receiver operating characteristic（ROC） curve（AUC） were analyzed. Deek's funnel plots were used to evaluate publication bias. Results A total of 10 eligible studies involving 1 360 patients were included in this Meta-analysis. The pooled sensitivity,specificity,PLR and NLR were 0.71 [95% confidence interval（CI） 0.63-0.79],0.94（95%CI 0.91-0.96）,11.3（95%CI 7.2-17.5） and 0.31（95%CI 0.23-0.41）,respectively. The AUC and DOR were 0.94（95%CI 0.92-0.96）and 37（95%CI 19-71）. Deek's funnel plots showed a publication bias. Conclusions ctDNA is potential for the auxiliary diagnosis of melanoma.

Key words: Circulating tumor DNA, Melanoma, Diagnostic value, Meta-analysis

CLC Number:

R446.1

WAN Wenting, YU Bo, GONG Mengchun, SHI Wenzhao, GUO Hao, YANG Jie. Value of circulating tumor DNA for the diagnosis of melanoma：a Meta-analysis[J]. Laboratory Medicine, 2020, 35(8): 784-790.

Figures/Tables 7

References 23

[1]	LUKE J J,FLAHERTY K T,RIBAS A,et al. Targeted agents and immunotherapies:optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol,2017,14(8):463-482.
[2]	BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[3]	CHI Z,LI S,SHENG X,et al. Clinical presentation,histology,and prognoses of malignant melanoma in ethnic Chinese:a study of 522 consecutive cases[J]. BMC Cancer,2011,11:85.
[4]	ALIX-PANABIÈRES C,SCHWARZENBACH H,PANTEL K. Circulating tumor cells and circulating tumor DNA[J]. Annu Rev Med,2012,63:199-215.
[5]	PINZANI P,SALVIANTI F,CASCELLA R,et al. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients[J]. Clin Chim Acta,2010,411(17-18):1319-1324.
[6]	TANG H,KONG Y,SI L,et al. Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma[J]. Oncol Lett,2018,15(2):1839-1844.
[7]	HASELMANN V,GEBHARDT C,BRECHTEL I,et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy[J]. Clin Chem,2018,64(5):830-842.
[8]	邬兰,张永,曾宪涛. QUADAS-2在诊断准确性研究的质量评价工具中的应用[J]. 湖北医药学院学报,2013,32(3):201-208.
[9]	MOSKO M J,NAKORCHEVSKY A A,FLORES E,et al. Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry[J]. J Mol Diagn,2016,18(1):23-31.
[10]	SANTIAGO-WALKER A,GAGNON R,MAZUMDAR J,et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials[J]. Clin Cancer Res,2016,22(3):567-574.
[11]	LONG-MIRA E,ILIE M,CHAMOREY E,et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients[J]. Oncotarget,2018,9(90):36238-36249.
[12]	JANKU F,HUANG H J,CLAES B,et al. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid,automated molecular diagnostics system[J]. Mol Cancer Ther,2016,15(6):1397-1404.
[13]	BOARD R E,ELLISON G,ORR M C M,et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244(ARRY-142886) advanced melanoma phase Ⅱ study[J]. Br J Cancer,2009,101(10):1724-1730.
[14]	AUNG K L,DONALD E,ELLISON G,et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system[J]. J Mol Diagn,2014,16(3):343-349.
[15]	ROWE S P,LUBER B,MAKELL M,et al. From validity to clinical utility:the influence of circulating tumor DNA on melanoma patient management in a real-world setting[J]. Mol Oncol,2018,12(10):1661-1672.
[16]	YANCVITZ M,YOON J,MIKHAIL M,et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma[J]. J Mol Diagn,2007,9(2):178-183.
[17]	梁维君. 医药统计学[M]. 7版. 北京:中国医药科技出版社,2006.
[18]	YANG Y C,WANG D,JIN L,et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients[J]. Biosci Rep,2018,38(4):BSR20180322.
[19]	LIM S H,BECKER T M,CHUA W,et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer[J]. Cancer Lett,2014,346(1):24-33.
[20]	刘毅,张少华,吴一龙,等. 中国临床肿瘤学进展 [M]. 北京:人民卫生出版社,2017.
[21]	WAN J C M,MASSIE C,GARCIA-COBACHO J,et al. Liquid biopsies come of age:towards implementation of circulating tumour DNA[J]. Nat Rev Cancer,2017,17(4):223-238.
[22]	SIRAVEGNA G,MARSONI S,SIENA S,et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
[23]	李慧敏,马清光,李洪英. 胸腔积液γ-干扰素释放试验对结核性胸腔积液诊断价值的Meta分析[J]. 检验医学,2018,33(2):139-146.